LATEST NEWS

BMG Pharma S.r.l. is pleased to announce the achievement of the ISO Certificate 13485 from TÜV Süd.

The Certificate issued by TÜV Süd America Inc., USA, certifies that BMG has established and is maintaining a quality management system that meets the requirements of ISO 13485:2003 and is in compliance with the Health Canada CMDCAS Recognized Registrar. The Certificate states that BMG is authorized for the design, development and manufacture of gel, cream and solutions for wound care, vaginal and oral mucosa treatment.

The second Certificate, issued by TÜV Süd Product Service GmbH, Germany, certifies that BMG has established and is maintaining a quality management system that meets the requirements of EN ISO 13485:2012 + AC:2012, ISO 13485:2003+ Cor. 1:2009 and DIN EN ISO 13485:2012.
The Certificate states that BMG is authorized for the design and development, production and distribution of gel, cream and solutions for wound, vaginal and oral mucosa treatment.

BMG Pharma S.r.l. is a specialty pharmaceutical company with head office in Milan, Italy, leveraging its proprietary technology to develop products that address unmet needs of patients. The Company is currently focused on cancer supportive care, dermatology gynecology, ENT and oralBMG Pharma S.r.l. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market.

The Company’s key features are:
– Full involvement in business and partnering
– Presence in different therapeutic areas
– Specific regulatory strategies for each product as Prescription and OTC Medical Devices in EC and US to
allow rapid market introduction. BMG focuses on bringing products to market quickly with supportive clinical
data.
– IP protection for most of the products and technologies.